Retatrutide Is Real. What’s Being Sold to You Isn’t.

About this video

In Arabic-captioned narration, Yurth explains retatrutide as Eli Lilly’s investigational next-generation metabolic drug, which she describes as targeting three receptors related to appetite and metabolism, unlike earlier drugs targeting fewer. She calls the late-stage trial results striking while warning that trial investigators themselves flagged muscle loss as a concern linked, in her explanation, to glucagon signalling and amino-acid use. Her central warning is regulatory: she states the drug is not yet approved and cannot legally be compounded, so anything sold as retatrutide today is, in her words, an unregulated research chemical without reliable purity or stability testing. She advises waiting for a legitimate product.

Key takeaways

• An exciting molecule is not the same as an available, approved medicine, Yurth stresses
• Treat any current offer of retatrutide as unregulated, in her warning
• Ask about muscle-loss concerns alongside weight-loss claims for metabolic drugs
• Spend the waiting time building muscle, Yurth suggests

Episode details: published September 16, 2026 · 3K views · 1:38 long. Summary written by Self Growth Videos from the episode itself. The longevity and peptide concepts described are Dr. Elizabeth Yurth’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Dr. Yurth is co-founder and Chief Medical Officer of the Boulder Longevity Institute, a clinic, and BLI Academy sells clinician education.

← Previous: The Future of Peptide Therapy: What Works, What Doesn’t, & What’s Coming Next · Next: The Biggest Longevity Mistake? Why More Isn’t Always Better | Dr. Elizabeth Yurth →

All Dr. Elizabeth Yurth videos · Dr. Elizabeth Yurth profile · Boulder Longevity Institute (official site)